These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29131323)

  • 1. Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy.
    Pearman TP; Beaumont JL; Mroczek D; O'Connor M; Cella D
    Cancer; 2018 Mar; 124(5):991-997. PubMed ID: 29131323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validity of a single-item indicator of treatment side effect bother in patients with head and neck cancer.
    Gharzai LA; Mierzwa ML; Stepan KO; Cella D; Peipert JD
    Support Care Cancer; 2024 Aug; 32(9):575. PubMed ID: 39107440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients.
    Griffiths P; Peipert JD; Leith A; Rider A; Morgan L; Cella D; Cocks K
    Support Care Cancer; 2022 Apr; 30(4):3613-3623. PubMed ID: 35031830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychometrics of patient-reported bother from side effects of treatment single-items in industry-sponsored oncology trials.
    Trask PC; Holt T; Pearman T
    Qual Life Res; 2023 Sep; 32(9):2601-2615. PubMed ID: 37119353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of baseline patient-reported side effect bother from cancer therapy.
    Roydhouse JK; King-Kallimanis BL; Roy P; Weinstock C; Krol D; Daniels SR; Suzman DL; Beaver JA; Kluetz PG
    Clin Trials; 2020 Jun; 17(3):332-337. PubMed ID: 32153216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma.
    Peipert JD; Zhao F; Lee JW; Shen SE; Ip E; O'Connell N; Carlos RC; Graham N; Smith ML; Gareen IF; Raper PJ; Weiss M; Kumar SK; Rajkumar SV; Cella D; Gray R; Wagner LI
    JAMA Netw Open; 2024 Mar; 7(3):e243854. PubMed ID: 38536173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?
    Peipert JD; Shaunfield S; Kaiser K; Moreno PI; Fox RS; Kircher S; Mohindra N; Ip E; Zhao F; Wagner L; Cella D
    Support Care Cancer; 2022 Dec; 31(1):37. PubMed ID: 36525100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the Functional Assessment of Cancer Therapy-Leukemia instrument in patients with acute myeloid leukemia who are not candidates for intensive therapy.
    Peipert JD; Yount SE; Efficace F; Loefgren C; Pierson R; He J; Cella D
    Cancer; 2020 Aug; 126(15):3542-3551. PubMed ID: 32463931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using Patient-reported Outcomes to Compare Relative Burden of Cancer: EQ-5D and Functional Assessment of Cancer Therapy-General in Eleven Types of Cancer.
    Pickard AS; Jiang R; Lin HW; Rosenbloom S; Cella D
    Clin Ther; 2016 Apr; 38(4):769-77. PubMed ID: 27041407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The FACT-GP5 as a global tolerability measure: responsiveness and robustness to missing assessments.
    Arizmendi C; Zhu Y; Khan M; Gable J; Reeve BB; King-Kallimanis B; Bell J
    Qual Life Res; 2024 Oct; 33(10):2869-2880. PubMed ID: 39046616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).
    Hagelstein V; Ortland I; Wilmer A; Mitchell SA; Jaehde U
    Ann Oncol; 2016 Dec; 27(12):2294-2299. PubMed ID: 27681863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acceptability of Routine Evaluations Using Patient-Reported Outcomes of Common Terminology Criteria for Adverse Events and Other Patient-Reported Symptom Outcome Tools in Cancer Outpatients: Princess Margaret Cancer Centre Experience.
    Albaba H; Barnes TA; Veitch Z; Brown MC; Shakik S; Su S; Naik H; Wang T; Liang M; Perez-Cosio A; Eng L; Mittmann N; Xu W; Howell D; Liu G
    Oncologist; 2019 Nov; 24(11):e1219-e1227. PubMed ID: 31409744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Basch E; Becker C; Rogak LJ; Schrag D; Reeve BB; Spears P; Smith ML; Gounder MM; Mahoney MR; Schwartz GK; Bennett AV; Mendoza TR; Cleeland CS; Sloan JA; Bruner DW; Schwab G; Atkinson TM; Thanarajasingam G; Bertagnolli MM; Dueck AC
    Clin Trials; 2021 Feb; 18(1):104-114. PubMed ID: 33258687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.
    Yoon J; Sim SH; Kang D; Han G; Kim Y; Ahn J; Oh D; Lee ES; Kong SY; Cho J; Mitchell SA
    J Pain Symptom Manage; 2020 May; 59(5):1082-1088.e6. PubMed ID: 32044423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial.
    O'Connell NS; Zhao F; Lee JW; Ip EH; Peipert JD; Graham N; Smith ML; Gareen IF; Carlos RC; Obeng-Gyasi S; Sparano JA; Shanafelt TD; Thomas ML; Cella D; Wagner LI; Gray R
    J Clin Oncol; 2024 Jan; 42(3):266-272. PubMed ID: 37801678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data.
    Smith EML; Banerjee T; Yang JJ; Bridges CM; Alberti P; Sloan JA; Loprinzi C
    Cancer Nurs; 2019; 42(3):179-189. PubMed ID: 29649081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating global treatment toxicity burden from adverse-event data.
    Lee SM; Hershman DL; Miao J; Zhong X; Unger JM; Cheung YKK
    Cancer; 2018 Feb; 124(4):858-864. PubMed ID: 29112232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.